Louisiana Attorney General Liz Murrill announced a $45 million settlement with CVS Health and its pharmacy benefit manager (PBM) subsidiary, resolving three separate lawsuits alleging deceptive and unfair practices. The agreement, reached on February 23, 2026, aims to address concerns over consumer privacy, regulatory compliance, and competitive harm to independent pharmacies within the state. This settlement marks a significant step toward increased accountability within the pharmaceutical industry and promises to bolster state initiatives focused on pharmacy benefit legislation and Medicaid fraud prevention.
The lawsuits, initially filed in June 2025, centered around a range of alleged misconduct by CVS Health and Caremark. According to the Attorney General’s office, these actions prioritized CVS’s financial interests over the well-being of both patients and independent pharmacies in Louisiana. The $45 million settlement will be allocated to support pharmacy benefit legislation and Medicaid fraud initiatives, working in collaboration with the Louisiana Department of Health and the Office of the Inspector General, as reported by the Louisiana Office of the Attorney General here.
Allegations of Misconduct
The three lawsuits tackled distinct areas of concern. One focused on the use of consumer personal information during lobbying efforts against a proposed state bill. Another alleged violations of regulatory practices, although the third claimed that CVS engaged in unfair competitive practices that negatively impacted Louisiana’s independent pharmacies. These practices, according to the Attorney General, created an uneven playing field and potentially limited patient access to care. The National Council of Prescription Drug Programs (NCPA) highlighted these manipulative tactics in a report on the settlement here.
Murrill emphasized that the decision to settle was strategic, designed to avoid a potentially lengthy and costly legal battle. “Rather than prolonging litigation, which could have extended several years, we worked with CVS to reach a resolution that serves the best interests of Louisiana,” she stated, as reported by WVLA Baton Rouge here. The funds secured through the settlement will be instrumental in strengthening oversight of pharmaceutical pricing and PBM industry practices.
CVS Response and Future Implications
CVS Health acknowledged the settlement, stating its commitment to lowering healthcare costs and maintaining community pharmacy access for Louisiana residents. A spokesperson for CVS Health indicated that the agreement “enables us to place this litigation behind us so we can continue to serve Louisiana residents,” as reported by Becker’s Hospital Review here. Although, the company explicitly stated that the settlement does not constitute an admission of liability or wrongdoing.
The resolution comes at a time of increasing scrutiny of pharmacy benefit managers and their role in driving up prescription drug costs. PBMs act as intermediaries between drug manufacturers, insurance companies, and pharmacies, and have faced criticism for practices that allegedly prioritize profits over patient access and affordability. The Louisiana settlement could set a precedent for other states considering similar legal action against PBMs. NOLA.com also covered the settlement, noting the Attorney General’s focus on protecting Louisiana citizens here.
Looking ahead, the Louisiana Department of Health and the Office of the Inspector General will collaborate to implement new pharmacy benefit legislation and enhance efforts to combat Medicaid fraud. The specific details of these initiatives are expected to be announced in the coming months. This settlement represents a significant victory for Louisiana taxpayers and a step toward a more transparent and equitable pharmaceutical marketplace.
This article provides informational content only and is not intended to be a substitute for professional legal or medical advice.
What are your thoughts on this settlement? Share your comments below and help us continue the conversation.
